诺泰生物(688076) - 诺泰生物投资者关系活动记录表（2024-002）

Group 1: Convertible Bond Issuance and Capacity Expansion - The company is currently constructing projects funded by the convertible bond issuance as planned, with production capacity utilization and order status to be monitored through official announcements [3] - The company’s peptide raw material production capacity has reached a ton-level scale, and the formulation capacity has significantly improved; the small molecule CDMO has a total capacity of approximately 124,000 liters [3] Group 2: Talent Development and Training - The company places high importance on talent cultivation and recruitment, planning to attract excellent talent through various channels such as campus and social recruitment [3] - A comprehensive training system will be established to provide employees with systematic professional knowledge and skills training [3]